# Phase 50 Frozen Scope Extract

Kickoff package only — **not** an implementation or Production Acceptance claim.

**Canonical base:** `release47-step22-transfer-20260810-0353` @ `15011902caa1d06559e91128fb1235366849c29f`  
**Phase 49:** ACCEPTED (merged PR #5) — Production Hardening closed for program purposes.  
**Do not reopen Wave A–I or Phase 49 SoR** except new product failure + CTO.

## Source authority (SSOT)

| Document / decision | Binding use |
|---------------------|-------------|
| CTO Phase 50 kickoff authorize (this package) | Program name, IN/OUT, slice order |
| `docs/PHASE_49_IMPLEMENTATION_REVIEW_PACKAGE/` + merge `1501190` | Closed Phase 49 evidence tip |
| Wave I PA ACCEPTED @ `9eac595` | Closed Phase 48 Enterprise QA |
| Existing a11y / clinic-dashboard / Super Admin UX surfaces | Prefer reuse — no second framework |

Exact file lists and gap rankings may be refined in D1 discovery; **Docs and UX Polish intent and OUT list are frozen for kickoff**.

---

## Official Phase 50 name

**Docs and UX Polish**

## Frozen intent (IN)

Phase 50 improves **operator clarity and bounded UX quality** on the accepted Release 47 + Phase 48 + Phase 49 lineage. Scope is documentation polish, thin UX/a11y follow-ups, and deferred UX candidates — not commercial launch or SoR reopen.

| Domain | Intent (freeze; implement only after CTO slice authorize) |
|--------|-----------------------------------------------------------|
| Docs polish / operator clarity | Tighten runbooks, cross-links, and operator-facing docs so day-2 paths are clearer without inventing new ops products |
| Bounded UX polish | Small, reviewable UI clarity fixes (labels, empty states, truncated identity display) — not a brand redesign |
| A11y follow-ups | Thin follow-ups on existing a11y expectations (landmarks, focus, status not color-only) where gaps are inventoried |
| AppointmentForm clinical-catalog picker | **Explicit candidate slice** — deferred identity binding from Wave H/I OUT; authorize separately if CTO chooses |
| Owner UX gaps (names vs truncated UUIDs) | **Candidates** for thin slices — show human-readable names where SoR already exposes them; no schema SoR rewrite |

**Framework reuse (frozen):**

```text
Prefer existing Step 28 / Step 29 + Clinic Dashboard / Super Admin CI philosophy
Prefer existing Playwright / Vitest / Jest patterns already in repo
Deterministic --runInBand / fail-closed evidence where tests are required
```

```text
Do not invent a second test framework or parallel “UX suite brand” without CTO amendment.
```

---

## Explicit OUT

| OUT | Why |
|-----|-----|
| Phase 51 commercial launch | Separate program |
| Wave A–I SoR reopen | Closed; reopen only on new product failure + CTO |
| Phase 49 Production Hardening SoR reopen | Closed @ `1501190`; reopen only on new product failure + CTO |
| Full brand redesign / polish dump | Violates “bounded” polish; dump ≠ thin slices |
| Second test framework | Violates reuse rule |
| Self-granted Phase 50 Production Acceptance | External / CTO only |
| New clinic product domains / schema SoR “while polishing” | Phase 50 ≠ Phase 48 feature waves |
| Fake production cutover / CI→CD conversion | Ops topology remains external (Phase 49 D-17) |

---

## Entry gates (for later implementation)

- Canonical tip includes Phase 49 merge `1501190` (or later accepted tip on same base lineage).
- Phase 48 Waves A–I and Phase 49 remain closed for SoR reopen purposes.
- Explicit CTO **implementation** authority for D1+ (D0 kickoff alone is insufficient).
- Agreed CI baselines remain green on accepting lineage.
